RxSight, Inc.(RXST)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,567 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in RXST
Events flagged as statistical outliers against RXST's own multi-year baseline — not fixed dollar thresholds.
- Score shock2026-08-05
RXST quality score dropped 9 points (32→23) on a new filing
View source filing →
RXST Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for RxSight, Inc. (RXST), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RXST at 28.1/100 on a 32-signal composite quality model, placing it at rank #2,567 of 2,962 stocks — the bottom half of the AI-ranked universe. RXST scores in the top quartile across institutional flow (77.6). Areas of concern include profitability (11.9) and free cash flow (12.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), RxSight, Inc. reports quarterly revenue of $33.7M, net income of $-12.1M, an operating margin of -40.8%. Top institutional holders of RXST by reported 13-F value include BlackRock, MILLENNIUM MANAGEMENT, No Street GP, based on the most recent SEC filings. RXST trades on the Nasdaq exchange and files with the SEC under CIK 1111485. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RXST daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for RxSight, Inc. directly from SEC EDGAR. RxSight, Inc.'s 13F Pro composite quality score has ranged between 18 and 40 since 2022, currently 28.1 — a declining long-term trajectory across 64 quarterly and live scoring snapshots.
Revenue
Q2 2026
$33.7M
Net Income
Q2 2026
$-12.1M
Free Cash Flow
Q2 2026
$-11.5M
Operating Margin
Q2 2026
-40.8%
ROIC
Q2 2026
-20.9%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-3.9% YoYNet Income
-41.8% YoYOperating Income
-30.7% YoYEPS (Diluted)
-33.8% YoYTotal Assets
-2.1% YoYTotal Debt
Op. Cash Flow
+8.5% YoYFree Cash Flow
+13.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $134.5M -3.9% | $139.9M +57.1% | $89.1M +81.8% | $49.0M +116.9% | $22.6M +53.9% | $14.7M |
| Net Income | $-38.9M -41.8% | $-27.5M +43.5% | $-48.6M +27.2% | $-66.8M -37.1% | $-48.7M -276.6% | $27.6M |
| Operating Income | $-48.2M -30.7% | $-36.9M +26.4% | $-50.1M +20.9% | $-63.3M -19.9% | $-52.8M -49.1% | $-35.4M |
| EPS (Diluted) | $-0.95 -33.8% | $-0.71 +49.6% | $-1.41 +41.5% | $-2.41 +32.5% | $-3.57 -2480.0% | $0.15 |
| Total Assets | $311.8M -2.1% | $318.6M +74.5% | $182.6M +21.6% | $150.2M -22.1% | $192.7M +91.4% | $100.7M |
| Total Debt | — | — | $0.00 -100.0% | $40.2M +1.0% | $39.8M +63.0% | $24.4M |
| Operating Cash Flow | $-15.5M +8.5% | $-16.9M +59.3% | $-41.6M +29.3% | $-58.9M -31.6% | $-44.7M -27.0% | $-35.2M |
| Free Cash Flow | $-19.3M +13.6% | $-22.4M +51.8% | $-46.4M +24.2% | $-61.2M -31.3% | $-46.6M -23.6% | $-37.7M |
Get alerted when RXST's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for RxSight, Inc. including:
Top Institutional Holders of RXST
BlackRock, Inc.
$27.9M5,790,408 shMILLENNIUM MANAGEMENT LLC
$14.6M3,030,287 shNo Street GP LP
$9.9M2,055,000 shNOMURA HOLDINGS INC
$9.6M2,000,060 shD. E. Shaw & Co., Inc.
$9.6M1,985,215 shVANGUARD CAPITAL MANAGEMENT LLC
$8.1M1,675,582 shAQR CAPITAL MANAGEMENT LLC
$7.4M1,533,826 shACADIAN ASSET MANAGEMENT LLC
$7.2M1,501,180 shFEDERATED HERMES, INC.
$5.8M1,201,195 shGrandeur Peak Global Advisors, LLC
$5.8M167,998 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $27.9M | 5,790,408 |
| MILLENNIUM MANAGEMENT LLC | $14.6M | 3,030,287 |
| No Street GP LP | $9.9M | 2,055,000 |
| NOMURA HOLDINGS INC | $9.6M | 2,000,060 |
| D. E. Shaw & Co., Inc. | $9.6M | 1,985,215 |
| VANGUARD CAPITAL MANAGEMENT LLC | $8.1M | 1,675,582 |
| AQR CAPITAL MANAGEMENT LLC | $7.4M | 1,533,826 |
| ACADIAN ASSET MANAGEMENT LLC | $7.2M | 1,501,180 |
| FEDERATED HERMES, INC. | $5.8M | 1,201,195 |
| Grandeur Peak Global Advisors, LLC | $5.8M | 167,998 |
Companies Similar to RXST
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
MAXCYTE, INC.
Entrada Therapeutics, Inc.
Keros Therapeutics, Inc.
ENANTA PHARMACEUTICALS INC
Alector, Inc.
Xencor Inc
Arcturus Therapeutics Holdings Inc.
Personalis, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put RXST on your watchlist
Track score changes the day RxSight, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is RXST a good stock to buy?
13F Pro's AI-powered analysis of RxSight, Inc. (RXST) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RXST are available on the RXST stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. RXST is classified as a small company.
Which hedge funds own RXST?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RXST. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of RxSight, Inc.'s investment landscape.